Companies

3 min read

Siemens Healthineers shares edge up 0.41%, broadly tracking Dax

Siemens Healthineers traded at €44.02 around midday on November 19, 2026, a modest gain after several weaker sessions. The move put the medical technology company in the middle third of Dax stocks, following its recent earnings report and announcements...

lake-av1wquo49a1aoxfadqulihev-0c433da2-8539-4cd2-b6b4-8269220bd4a0-0.webp

AI summary

  • Siemens Healthineers reported fiscal fourth-quarter revenue of €6.784 billion, up 7.3% from a year earlier.
  • Adjusted EBIT fell 2.0% to €1.077 billion in the quarter, with a margin of 15.9%.
  • Comparable revenue rose 10.0% in Imaging and 4.8% in Precision Therapy, but fell 4.2% in Diagnostics.
  • The company forecasts fiscal 2027 comparable revenue growth of 4.0% to 5.0%, below the 5.5% analyst expectation reported by Reuters.
  • Siemens Healthineers expects a slight decline in China in fiscal 2027 amid centralized procurement and pricing pressure.

Shares and trading volume

The stock rose from a previous close of €43.84, ranking 15th by daily performance as the Dax advanced 0.33%. The snapshot from EOD Historical Data was timestamped 12:55 p.m. on November 19; quotes may be delayed.

At that point, 186,712 shares had changed hands, versus 910,816 during the entire preceding trading day. The price was 4.62% below the stock's 52-week high of €46.15. Its low over that period was €32.81.

Siemens Healthineers ranks 14th by Dax weighting, accounting for 2.28% of the index, with a free-float market value of €49.07 billion. SAP, Siemens and Allianz have the largest weights.

Revenue rises as quarterly adjusted profit falls

In results released November 5, Siemens Healthineers reported revenue of €6.784 billion for its fiscal fourth quarter, which ended September 30, 2026. That was a 7.3% increase from a year earlier, or 5.9% on a comparable basis. Adjusted EBIT fell 2.0% to €1.077 billion, with a margin of 15.9%, while adjusted basic earnings per share were €0.69.

Performance differed across the businesses: comparable revenue rose 10.0% in Imaging and 4.8% in Precision Therapy, but fell 4.2% in Diagnostics.

For fiscal 2026, which also ended September 30, comparable revenue grew 4.0%. The company recorded about €3.8 billion in adjusted EBIT and a 16.2% adjusted EBIT margin. Adjusted basic earnings per share totaled €2.42, and free cash flow was about €2.4 billion. Its proposed dividend of €1.00 per share would leave the payout unchanged from the prior year.

Fiscal 2027 forecast and pressure in China

Siemens Healthineers expects comparable revenue growth of 4.0% to 5.0% in fiscal 2027, below the 5.5% analyst expectation reported by Reuters. Its forecast for adjusted basic earnings per share is €2.20 to €2.40, compared with analysts' €2.37 estimate.

China, the company's second-largest market after the US, contributes about 10% of group revenue. Diagnostics revenue there dropped more than 30% in fiscal 2026, while fourth-quarter group revenue in China fell 2%. The company assumes a slight decline in China in fiscal 2027 amid centralized procurement and pricing pressure.

The outlook also includes the effect of winding down roughly €150 million of general imaging ultrasound operations within an ultrasound business totaling about €600 million. Siemens Healthineers plans to close those operations rather than sell them, diluting fiscal 2027 revenue growth by about 70 basis points.

Diagnostics separation and Siemens ownership plans

Alongside the annual results, Siemens Healthineers announced plans to shorten its corporate name to "Healthineers" and began the process of carving out Diagnostics. It aims to establish Diagnostics as a standalone company by mid-2028, with a mid-teens margin ambition supported by an additional €400 million in cost savings.

Separately, Siemens AG plans a direct spin-off during fiscal 2027 to reduce its stake in Siemens Healthineers and deconsolidate the company. Under the plan, Siemens would transfer 34.1% of its stake in Siemens Healthineers to its shareholders, who would receive one Siemens Healthineers share for every two Siemens shares. Until completion, Siemens Healthineers' results will be reported as discontinued operations.

#Siemens
← Back to Companies

Related news